MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

106.2

-0.66%↓

WBA

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

106.2

-0.66%↓

WBA

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

106.2

-0.66%↓

WBA

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

106.2

-0.66%↓

WBA

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

106.2

-0.66%↓

WBA

-0.18%↓

CHE

555.98

+1.76%↑

Kodu・Aktsiate loetelu・Verve Therapeutics Inc

Verve Therapeutics Inc

Suletud

5.74 -0.35

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

5.69

Max

5.8

Põhinäitajad
By Trading Economics
Sissetulek	98K -50M
Müük	6.2M 13M
Aktsiakasum	-0.58
Kasumimarginaal	-382.531
Töötajad	274
EBITDA	789K -54M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+338.37% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	8. mai 2025

Turustatistika
By TradingEconomics
Turukapital	-171M 424M
Eelmine avamishind	6.09
Eelmine sulgemishind	5.74

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

4.78 / 5.78 Toetus ja vastupanu

Verve Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. apr 2025, 23:55 UTC

Market Talk

Oil Edges Higher Amid Hopes for Easing U.S.-China Trade Tensions -- Market Talk

27. apr 2025, 23:47 UTC

Market Talk

Gold Falls Amid Dollar Strength, Signs of Easing U.S.-China Trade Tensions -- Market Talk

27. apr 2025, 23:42 UTC

Market Talk

Nikkei May Rise as Fears About U.S.-China Tensions Ebb -- Market Talk

27. apr 2025, 23:12 UTC

Tulu

Sinopharm Group 1Q Rev CNY141.66B Vs. CNY147.27B >1099.HK

27. apr 2025, 23:12 UTC

Tulu

Sinopharm Group 1Q Net CNY1.46B Vs. Net CNY1.42B >1099.HK

27. apr 2025, 20:41 UTC

Tulu

Pharmaron Beijing 1Q Net CNY305.58M Vs. Net CNY230.56M >300759.SZ

27. apr 2025, 20:41 UTC

Tulu

Pharmaron Beijing: Higher Contributions From Laboratory Services Among Factors Supporting Results> 300759.SZ

27. apr 2025, 20:41 UTC

Tulu

Pharmaron Beijing 1Q Rev CNY3.10B Vs. CNY2.67B >300759.SZ

27. apr 2025, 18:41 UTC

Peamised uudised

Bessent Doesn't Know If Trump and Xi Have Talked on Trade -- Barrons.com

27. apr 2025, 11:00 UTC

Peamised uudised

Wall Street's New Tariff Safe Haven: High-Tax Biotech Stocks -- Heard on the Street -- WSJ

27. apr 2025, 05:41 UTC

Tulu

China Everbright Bank 1Q Net CNY12.46B Vs. Net CNY12.43B >601818.SH

27. apr 2025, 05:41 UTC

Tulu

China Everbright Bank: Lower Net Interest Income Weighed on Operating Income>601818.SH

27. apr 2025, 05:41 UTC

Tulu

China Everbright Bank 1Q Operating Income CNY33.10B Vs. CNY34.49B>601818.SH

27. apr 2025, 05:41 UTC

Tulu

China Everbright Bank 1Q Impairment Loss on Credit Assets Was CNY8.49B; Down 15.6% on Year>601818.SH

27. apr 2025, 05:41 UTC

Tulu

China Everbright Bank 1Q Operating Expenses Was CNY9.15B; Down 3.2%>601818.SH

27. apr 2025, 05:41 UTC

Tulu

China Everbright Bank 1Q Net Interst Income Was CNY22.54B; Down 6.8% on Year>601818.SH

27. apr 2025, 05:34 UTC

Tulu

Chongqing Rural Commercial Bank: 1Q Results Supported by Higher Net Interest Income>3618.HK

27. apr 2025, 05:34 UTC

Tulu

Chongqing Rural Commercial Bank 1Q Operating Income CNY7.22B Vs. CNY7.13B>3618.HK

27. apr 2025, 05:34 UTC

Tulu

Chongqing Rural Commercial Bank 1Q Net CNY3.75B Vs. Net CNY3.52B >3618.HK

27. apr 2025, 05:29 UTC

Tulu

China Shenhua Energy: Results Weighed by Fall in Selling Prices of Coal >1088.HK

27. apr 2025, 05:29 UTC

Tulu

China Shenhua Energy 1Q Net CNY13.37B Vs. Net CNY17.76B >1088.HK

27. apr 2025, 05:29 UTC

Tulu

China Shenhua Energy 1Q Rev CNY69.59B Vs. CNY87.65B >1088.HK

27. apr 2025, 05:29 UTC

Tulu

China Shenhua Energy: Lower Revenue From Electricity Sales Also Hurt Results >1088.HK

27. apr 2025, 05:21 UTC

Tulu

CMOC Group 1Q Net CNY3.95B Vs. Net CNY2.07B >3993.HK

27. apr 2025, 05:21 UTC

Tulu

CMOC Group: Cost Cuts Also Among Factors that Boosted 1Q Net >3993.HK

27. apr 2025, 05:21 UTC

Tulu

CMOC Group 1Q Rev CNY46.01B Vs. CNY46.12B >3993.HK

27. apr 2025, 05:21 UTC

Tulu

CMOC Group: Increase in Prices of Copper, Cobalt Supported Results>3993.HK

27. apr 2025, 03:00 UTC

Peamised uudised

Chinese Manufacturers Are Scouring the World for New Buyers -- WSJ

27. apr 2025, 00:30 UTC

Peamised uudised

Meta's 'Digital Companions' Will Talk Sex With Users -- Even Children -- WSJ

27. apr 2025, 00:30 UTC

Peamised uudised

Meta's 'Digital Companions' Will Talk Sex With Users -- Even Children -- WSJ -2-

Võrdlus sarnastega

Hinnamuutus

Verve Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

338.37% tõus

12 kuu keskmine prognoos

Keskmine 25.25 USD 338.37%

Kõrge 39 USD

Madal 15 USD

Põhineb 10 Wall Streeti analüütiku instrumendi Verve Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

10 ratings

Osta

Hoia

Müü

Põhineb 10 analüütiku instrumendi Verve Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

4.78 / 5.78Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bearish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Verve Therapeutics Inc

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.